A former East End company that was marrying machine learning to surgery has won a federal $40 million breach of contract lawsuit, with the prospect of the final award going much higher.

In a five-count civil lawsuit filed last year in the United States District Court for the Southern District of New York, ChemImage Corp. alleged that Ethicon Inc. had improperly ended its research and development contract with ChemImage, entitling the company to the $40 million termination fee stipulated in its agreement. Ethicon argued that it had ended the contract because ChemImage had failed to reach a development milestone by April 2023.

U.S. District Court Judge Jesse M. Furman issued the ruling May 30.

ChemImage is also seeking as much as $84.6 million for the market value loss to its advanced imaging technology that resulted from the contract breach. After the contract was canceled in March 2023, the company was forced to lay off about 75 staff members and close two months later.

Advertise with us

Still to be determined by the court is which company will retain the license to ChemImage’s intellectual property.

Regardless of the determination, ChemImage will not be reborn, said former president and chief medical officer Jeffrey Cohen, adding that he was pleased with the ruling.

“We had a world-class labor force and they accomplished incredible things,” Dr. Cohen said. “The work that we did was groundbreaking. But it killed a promising company.”

Ethicon attorney Rachel B. Sherman, from the New York law firm of Patterson Belknap Webb & Tyler LLP, was not immediately available for comment.

In 2019, ChemImage and Ethicon inked a contract to jointly develop surgical visualization technology that surgeons could use to differentiate various kinds of tissue while operating, either manually or with robotic aid. The technology could greatly aid surgeons in identifying cancer for removal, for example, while sparing healthy tissue.

Advertise with us

More importantly, the results would be available in real time instead of waiting for pathology analysis.

Under the agreement, Ethicon agreed to pay ChemImage up to $174 million, including $7 million upfront and $149 million in payments if certain milestones were met.

Former University of Pittsburgh assistant professor of chemistry Patrick Treado founded ChemImage in 2002 as a university spinout, an early life sciences startup in Pittsburgh.

Raritan, N.J.-based Ethicon, a subsidiary of Johnson & Johnson, was founded in 1915 and markets a wide array of surgical products, including sutures and mesh products. In recent years, the company has been involved in costly litigation, including a $302 million settlement in 2020 with the state of California for deceptive marketing of pelvic mesh devices.